Tissue Regenix Group PLC OrthoPure(R)XT clinical results presentation
April 28 2022 - 2:02AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
28 April 2022
Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
OrthoPure(R) XT clinical results presentation
Clinical results presented for OrthoPure(R) XT at 20(th) ESSKA
Congress in Paris, France
Tissue Regenix Group (AIM:TRX), the regenerative medical devices
company, announces that a podium presentation on the clinical
experience with the Company's OrthoPure(R) XT, a novel xenograft
biologic scaffold for certain anterior cruciate ligament (ACL)
reconstruction procedures, will be presented at the 20(th) ESSKA
(European Society for Sports Traumatology, Knee Surgery and
Arthroscopy) Congress in Paris, France. At the conference,
clinician Mr. Neil Hunt, the principal investigator for the study,
will be presenting clinical results on the device's clinical safety
and performance from a recently completed long-term prospective
study.
OrthoPure (R) XT was awarded a CE Mark in June 2020 for revision
of ACL reconstruction procedures and reconstruction of other knee
ligaments, including multiligament and primary procedures when the
autograft is unacceptable.
Mr. Neil Hunt is a consultant knee surgeon at York Teaching
Hospitals NHS Foundation Trust, specialising in all aspects of knee
surgery. He will be presenting data on Tissue Regenix's
OrthoPure(R) XT ligament reconstruction implant which conclude that
patients undergoing primary ACL reconstruction with this implant
showed appropriate clinical safety and clinical performance at 48
months following treatment. These outcomes are in line with
clinical expectations following primary ACL reconstruction and they
indicate that OrthoPure(R) XT might provide an alternative graft
choice for ACL reconstruction and other ligament reconstructions.
Further studies are planned to evaluate this.
Further information on the abstract can be found here :
Title: First In Human Clinical Data From A Novel Xenograft
Biologic Scaffold Used To Treat Primary ACL Reconstruction.
24 & 48 Month Follow-Up
The ESSKA Congress brings together industry experts in sports
traumatology, knee surgery, and arthroscopy of ankle, knee, hip,
shoulder, elbow and wrist and provides varied and innovative
session formats covering all the latest updates, trends and
techniques in these areas. More information on the conference can
be found here.
Mr. Hunt, Consultant Knee Surgeon at York Teaching Hospitals NHS
Foundation Trust , commented: "I am encouraged by the results of
the 4-year clinical study with the OrthoPure(R) XT and look forward
to additional clinical experience with this device. The OrthoPure
(R) XT can be a biologic alternative which avoids the need to
source a graft from the patient for knee ligament surgeries."
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44(0)20 7710 7600
and Broker)
Ben Maddison / Nick Harland
Walbrook PR Ltd Tel: +44 (0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissuergenix.com)
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or damaged body structures. Current
applications address many critical clinical needs such as in sports
medicine, foot and ankle, and wound care.
In August 2017 Tissue Regenix acquired CellRight
Technologies(R), a biotech company that specializes in regenerative
medicine and is dedicated to the development of innovative
osteoinductive and wound care scaffolds that enhance healing
opportunities of defects created by trauma and disease. CellRight's
human osteobiologics may be used in spine, trauma, general
orthopaedic, dental, and ophthalmological surgical procedures.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASEMFMWEESEDL
(END) Dow Jones Newswires
April 28, 2022 02:02 ET (06:02 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2024 to Jun 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2023 to Jun 2024